Omecamtiv mecarbil: a new cardiac myosin activator for the treatment of heart failure

LCY Liu, B Dorhout, P van der Meer… - Expert opinion on …, 2016 - Taylor & Francis
Introduction: Current available inotropic agents increase cardiac contractility, but are
associated with myocardial ischemia, arrhythmias, and mortality. A novel selective cardiac …
被引用次数：62 相关文章

Omecamtiv mecarbil: a new cardiac myosin activator for the treatment of heart failure.

LC Liu, B Dorhout, P van der Meer… - Expert Opinion on …, 2015 - europepmc.org
Current available inotropic agents increase cardiac contractility, but are associated with
myocardial ischemia, arrhythmias, and mortality. A novel selective cardiac myosin activator …
[PDF] rug.nl

[PDF][PDF] Omecamtiv Mecarbil: a Novel Cardiac Myosin Activator for the Treatment of Heart Failure

LCY Liu, B Dorhout, P van der Meer… - Novel Therapies in …, 2016 - research.rug.nl
Introduction Current available inotropic agents increase cardiac contractility, but are
associated with myocardial ischemia, arrhythmias, and mortality. A novel selective cardiac …

Omecamtiv mecarbil: a new cardiac myosin activator for the treatment of heart failure

LC Liu, B Dorhout, P van der Meer… - Expert opinion on …, 2016 - pubmed.ncbi.nlm.nih.gov
Introduction Current available inotropic agents increase cardiac contractility, but are
associated with myocardial ischemia, arrhythmias, and mortality. A novel selective cardiac …

Omecamtiv mecarbil: a new cardiac myosin activator for the treatment of heart failure

LCY Liu, B Dorhout, P van der Meer… - Expert opinion on …, 2016 - research.rug.nl
Introduction: Current available inotropic agents increase cardiac contractility, but are
associated with myocardial ischemia, arrhythmias, and mortality. A novel selective cardiac …